ID   LIM1215
AC   CVCL_2574
SY   Lim1215; LIM 1215; LIM-1215
DR   BTO; BTO:0001916
DR   BioSample; SAMN07624413
DR   CBA; CBA-0161
DR   Cell_Model_Passport; SIDM00014
DR   ColonAtlas; LIM1215
DR   Cosmic; 869795
DR   Cosmic; 1184335
DR   Cosmic; 1238050
DR   Cosmic; 1479632
DR   Cosmic; 1482515
DR   Cosmic; 1486135
DR   Cosmic; 1524335
DR   Cosmic; 1676746
DR   Cosmic; 1805257
DR   Cosmic; 2301991
DR   Cosmic; 2667967
DR   Cosmic-CLP; 2162949
DR   DepMap; ACH-001546
DR   ECACC; 10092301
DR   GDSC; 869795
DR   GDSC; 2162949
DR   GEO; GSM741246
DR   GEO; GSM1346878
DR   GEO; GSM1448118
DR   PharmacoDB; LIM1215_836_2019
DR   PRIDE; PXD000120
DR   PRIDE; PXD005235
DR   Wikidata; Q54902517
RX   PubMed=1427983;
RX   PubMed=3857372;
RX   PubMed=9328464;
RX   PubMed=9515795;
RX   PubMed=12615714;
RX   PubMed=19378335;
RX   PubMed=20570890;
RX   PubMed=22722830;
RX   PubMed=23458625;
RX   PubMed=24295106;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=28854368;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   From: Ludwig Institute for Cancer Research, Melbourne branch; Melbourne; Australia.
CC   Doubling time: 32 hours, at 8th passage (PubMed=3857372); 28 hours (PubMed=142798).
CC   Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=25926053).
CC   Sequence variation: Heterozygous for ACVR2A p.Pro423Gln (c.1268C>A) and p.Lys437fs*5 (c.1310delA) (PubMed=12615714).
CC   Sequence variation: CTNNB1 p.Thr41Ala (c.121A>G) (PubMed=24755471).
CC   Sequence variation: Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (PubMed=12615714).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: N-glycan profiling.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=5.72%; Native American=0%; East Asian, North=3.18%; East Asian, South=0%; South Asian=6.91%; European, North=26.95%; European, South=57.24% (PubMed=30894373).
CC   Derived from metastatic site: Omentum.
ST   Source(s): CBA; PubMed=11416159; PubMed=25926053
ST   Amelogenin: X,Y (CBA; PubMed=25926053)
ST   Amelogenin: X (PubMed=11416159)
ST   CSF1PO: 10
ST   D13S317: 8,12
ST   D16S539: 8,12 (CBA)
ST   D16S539: 8,9,11,12 (PubMed=25926053)
ST   D18S51: 12,18
ST   D19S433: 10,15.2
ST   D21S11: 29,31
ST   D2S1338: 16,21
ST   D3S1358: 15,16
ST   D5S818: 9,12
ST   D7S820: 9,10.3
ST   D8S1179: 13 (CBA)
ST   D8S1179: 11,13 (PubMed=11416159)
ST   FGA: 21,23,24
ST   TH01: 9.3,10
ST   TPOX: 8
ST   vWA: 16 (CBA; PubMed=11416159)
ST   vWA: 15,16 (PubMed=25926053)
DI   NCIt; C4349; Colon adenocarcinoma
DI   NCIt; C8494; Lynch syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 26
RX   PubMed=1427983; DOI=10.1038/icb.1992.30;
RA   Whitehead R.H., Zhang H.H., Hayward I.P.;
RT   "Retention of tissue-specific phenotype in a panel of colon carcinoma
RT   cell lines: relationship to clinical correlates.";
RL   Immunol. Cell Biol. 70:227-236(1992).
RX   PubMed=3857372; DOI=10.1093/jnci/74.4.759;
RA   Whitehead R.H., Macrae F.A., St John D.J.B., Ma J.;
RT   "A colon cancer cell line (LIM1215) derived from a patient with
RT   inherited nonpolyposis colorectal cancer.";
RL   J. Natl. Cancer Inst. 74:759-765(1985).
RX   PubMed=9328464; DOI=10.1093/hmg/6.12.2011;
RA   Kilian A., Bowtell D.D.L., Abud H.E., Hime G.R., Venter D.J.,
RA   Keese P.K., Duncan E.L., Reddel R.R., Jefferson R.A.;
RT   "Isolation of a candidate human telomerase catalytic subunit gene,
RT   which reveals complex splicing patterns in different cell types.";
RL   Hum. Mol. Genet. 6:2011-2019(1997).
RX   PubMed=9515795;
RA   Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.;
RT   "Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal
RT   cancer.";
RL   Cancer Res. 58:1130-1134(1998).
RX   PubMed=12615714;
RA   Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A.,
RA   Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D.,
RA   Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.;
RT   "Evidence of selection for clones having genetic inactivation of the
RT   activin A type II receptor (ACVR2) gene in gastrointestinal cancers.";
RL   Cancer Res. 63:994-999(2003).
RX   PubMed=19378335; DOI=10.1002/ijc.24289;
RA   Zhang H.H., Walker F., Kiflemariam S., Whitehead R.H., Williams D.,
RA   Phillips W.A., Mikeska T., Dobrovic A., Burgess A.W.;
RT   "Selective inhibition of proliferation in colorectal carcinoma cell
RT   lines expressing mutant APC or activated B-Raf.";
RL   Int. J. Cancer 125:297-307(2009).
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
RX   PubMed=22722830; DOI=10.1038/nature11156;
RA   Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D.,
RA   Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K.,
RA   Cercek A., Chen C.-T., Veronese S., Zanon C., Sartore-Bianchi A.,
RA   Gambacorta M., Gallicchio M., Vakiani E., Boscaro V., Medico E.,
RA   Weiser M., Siena S., Di Nicolantonio F., Solit D., Bardelli A.;
RT   "Emergence of KRAS mutations and acquired resistance to anti-EGFR
RT   therapy in colorectal cancer.";
RL   Nature 486:532-536(2012).
RX   PubMed=23458625; DOI=10.1021/pr3010869;
RA   Fanayan S., Smith J.T., Lee L.Y., Yan F., Snyder M., Hancock W.S.,
RA   Nice E.;
RT   "Proteogenomic analysis of human colon carcinoma cell lines LIM1215,
RT   LIM1899, and LIM2405.";
RL   J. Proteome Res. 12:1732-1742(2013).
RX   PubMed=24295106; DOI=10.1021/pr400861m;
RA   Sethi M.K., Thaysen-Andersen M., Smith J.T., Baker M.S., Packer N.H.,
RA   Hancock W.S., Fanayan S.;
RT   "Comparative N-glycan profiling of colorectal cancer cell lines
RT   reveals unique bisecting GlcNAc and alpha-2,3-linked sialic acid
RT   determinants are associated with membrane proteins of the more
RT   metastatic/aggressive cell lines.";
RL   J. Proteome Res. 13:277-288(2014).
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002-7002(2015).
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).